Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,191
Next Earnings DateN/A
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Thursday, August, 1st. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.09. The company had revenue of $178 million for the quarter, compared to the consensus estimate of $171.97 million. Akorn had a negative return on equity of 17.88% and a negative net margin of 72.25%. Akorn's revenue for the quarter was down 6.8% compared to the same quarter last year. View Akorn's Earnings History.
What guidance has Akorn issued on next quarter's earnings?
Akorn issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $692.99 million.
What price target have analysts set for AKRX?
4 equities research analysts have issued twelve-month price targets for Akorn's shares. Their forecasts range from $4.00 to $11.00. On average, they expect Akorn's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 79.0% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
News coverage about AKRX stock has trended negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akorn earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Akorn.
Are investors shorting Akorn?
Akorn saw a decline in short interest in September. As of September 30th, there was short interest totalling 10,920,000 shares, a decline of 13.0% from the August 30th total of 12,550,000 shares. Based on an average trading volume of 1,920,000 shares, the days-to-cover ratio is presently 5.7 days. Currently, 11.6% of the company's shares are short sold. View Akorn's Current Options Chain.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Prestige Consumer Healthcare (PBH), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Apellis Pharmaceuticals (APLS), Pacira Biosciences (PCRX), Aimmune Therapeutics (AIMT), Tricida (TCDA) and Insmed (INSM).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.
Which institutional investors are buying Akorn stock?
AKRX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $3.91.
How big of a company is Akorn?
Akorn has a market capitalization of $492.07 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
